Rice Hall James & Associates purchased 574,877 shares of QuidelOrtho in Q4, increasing its stake to 833,791 shares valued at $23.8 million (1.3% of fund assets). The investment reflects confidence in the diagnostic technology company despite its stock being down 43.4% over the past year, as value investors anticipate improved financial results from recent leadership changes and strategic adjustments.

QuidelOrtho board director Matthew Strobeck purchased 10,000 shares for ~$240,000 on Feb. 13, 2026, as the company faces another executive transition with CFO Joseph Busky's retirement effective in June. The diagnostics company continues struggling with its third consecutive year of declining revenue and net losses, with stock down ~44% over the past year.

Law firm investigating potential claims against QuidelOrtho for allegedly misleading investors about COVID-19 test revenues and product launch during 2022-2024, with significant earnings miss and revenue forecast reduction in February 2024.

The global lateral flow assay market is projected to grow from $8.2 billion in 2024 to $12.6 billion by 2030, with a 7.5% CAGR. North America is expected to lead market growth, driven by advanced healthcare infrastructure and rapid diagnostic innovations.

QuidelOrtho reported Q2 FY2025 financial results with narrowly surpassed revenue estimates, improved adjusted EPS, and significant restructuring charges, reflecting ongoing market contraction and strategic shifts in diagnostic testing solutions.

The global molecular diagnostics for infectious disease market is poised for growth, driven by advancements in biotechnology and genomics, as well as the impact of multiplex assays on diagnosis and treatment. The report covers dynamic trends, including pathogen evolution, globalization, and climate change impacts, and provides insights on the U.S. Medicare Fee Schedules and global data.

The metastatic colorectal cancer clinical trial pipeline is accelerating, with over 150 pharmaceutical companies rigorously developing drugs for market entry. This indicates a positive sentiment for the industry as it aims to address the rising incidence of the disease.

The global immunodiagnostics market is expected to grow significantly, driven by the rising prevalence of chronic and infectious diseases, the increasing need for point-of-care testing, and the surge in product launches.

The global lateral flow assay market is expected to grow at a CAGR of 7.46% from 2025 to 2030, driven by increasing infectious disease incidences, rising demand for point-of-care testing, and advancements in home-based diagnostic kits. Key players like Abbott and Roche are driving innovation in this market.

The global drug screening market is expected to grow from $6.45 billion in 2024 to $10.34 billion by 2034, driven by the rising prevalence of substance use disorder and stringent regulatory policies. Technological advancements, such as lab-on-a-chip technology, are also expected to drive market growth.

The Immunoassay Analyzers Market is projected to grow from $7.55 billion in 2023 to $10.16 billion by 2032, driven by the increasing prevalence of chronic diseases, rising demand for early disease detection, and advancements in immunoassay technology.

The global lateral flow assays market is expected to grow from $9.65 billion in 2024 to $11.66 billion by 2030, driven by advancements in lateral flow assay technologies, increasing adoption of point-of-care testing, and rising demand in clinical diagnostics, environmental, and food industries.